The invention relates to a method for determining whether a subject has or is susceptible to developing a primary immunodeficiency (PID), the method comprising using a linear mixed model to fit a transcriptome profile of the subject to a PID prediction equation developed by fitting into a linear mixed model a transcriptomic relationship matrix generated from a reference set of transcriptome profiles of reference subjects with and without PID, wherein the prediction equation's result indicates whether the subject has or is susceptible to PID. The invention relates to a method for developing a primary immunodeficiency (PID) prediction equation for determining whether a subject has or is susceptible to developing a PID, the method comprising fitting into a linear mixed model a transcriptomic relationship matrix generated from a reference set of transcriptome profiles of reference subjects with and without PID to develop the PID prediction equation.

The present invention relates to a ratio of immune cells for use in a method of predicting therapeutic success of an allergen-specific immunotherapy (AIT) in a patient suffering from or having a disposition to develop an allergic disease. Furthermore, the present invention also relates to a kit for predicting therapeutic success of an allergen-specific immunotherapy in a patient suffering from or having a disposition to develop an allergic disease. Furthermore, the present invention relates to a method of predicting therapeutic success of an allergen-specific immunotherapy (AIT) in a patient suffering from or having a disposition to develop an allergic disease.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

An apparatus for detecting an analyte, the apparatus includes a biosensor having at least a sensor surface functionalized with a binding ligand, wherein the at least a sensor surface is configured to selectively bind to an analyte, a microfluidic device configured to receive a sample fluid containing the analyte, incubate the biosensor with the sample fluid, and conjugate an anti-analyte molecule with a nanoparticle, wherein the nanoparticle is configured to provide a binding signal to the biosensor when the nanoparticle binds to the analyte bound to the binding ligand on the at least a sensor surface, and incubate the biosensor with the analyte bound to the binding ligand on the at least a sensor surface with the anti-analyte molecule conjugated with the nanoparticle, and a sensor circuit communicatively connected to the biosensor, wherein the sensor circuit is configured to detect at least an analyte characteristic of the analyte.

The multiple allergen testing system includes an applicator and a fluid tray. The fluid tray is cooperatively engageable with the applicator. The applicator has an allergen loading position and an allergen deposition position. In the allergen loading position, a different allergen is loaded onto each respective scratching barb from each respective reservoir of the loading tray. Each scratching barb is designed to retain a trace of allergen fluid. A pair of finger grips are positioned on opposing sides of the applicator frame. The applicator fits into one hand of a medical technician administering the allergen skin testing. The applicator is removed from the fluid tray and repositioned onto the skin of the patient. The applicator is made of compressible material. In the allergen deposition position, the applicator is compressed, and each allergen is deposited into each respective scratch generated by each respective scratching barb on the skin for further analysis.

The invention provides Cockroach proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses and medicaments of such proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof. Such methods, uses and medicaments include modulating an immune response, protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease and inducing immunological tolerance to the allergen (e.g., Cockroach allergen) in a subject.

Quantitation of specific antibodies for at least one redox form of High mobility group box 1 (HMGB1) contained in a biological sample. An in vitro method for assessing the state of progression of a disease or a disorder in which HMGB1 is involved. An in vitro method for the identification of predisposition, prognostic or diagnostic biomarkers of a disease or a disorder in which HMGB1 is involved. A kit to quantitate said specific antibodies for at least one redox form of HMGB1.

The invention relates to the quantitation of specific antibodies for at least one redox form of High mobility group box 1 (HMGB1) contained in a biological sample, in particular human serum and/or Cerebrospinal Fluid (CSF). The invention also relates to an in vitro method for assessing the state of progression of a disease or a disorder in which HMGB1 is involved, to an in vitro method for the identification of predisposition, prognostic or diagnostic biomarkers of a disease or a disorder in which HMGB1 is involved. The invention also relates to a kit to quantitate said specific antibodies for at least one redox form of HMGB1, in particular human HMGB1.

In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-depleting agent based upon the subject's metabolic profile.